title: Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
abstract: The matrix fentanyl membrane patch is a new transdermal patch designed with a reduced drug load compared with established reservoir and matrix fentanyl patches. The drug is contained within a silicone matrix with a rate-controlling membrane designed to maintain constant serum fentanyl concentrations over the 72-hour application period. The matrix fentanyl membrane patch was equivalent to the reservoir fentanyl patch in terms of transdermal delivery of fentanyl, as demonstrated after both single (100 microg/h) and multiple (50 microg/h) applications by the peak serum fentanyl concentration and the area under the serum concentration-time curve over 72 hours. In a randomized, nonblind, multicentre trial, the transdermal matrix fentanyl membrane patch was noninferior to standard opioid therapy (transdermal reservoir or matrix fentanyl patch or an oral opioid) in terms of analgesic efficacy over 30 days in patients with cancer-related chronic pain requiring long-term opioid use. The transdermal matrix fentanyl membrane patch was as well tolerated as standard opioid therapy; patient-rated tolerability scores for constipation, nausea, daytime drowsiness and sleep disturbance were similar between treatments.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand.
authors.forename: Philip I
authors.initials: PI
authors.lastname: Hair
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002908:Chronic Disease; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl
references.citation: Drugs. 1997 Jan;53(1):109-38
references.pmid: 9010652
references.citation: Drugs. 2008;68(12):1711-21
references.pmid: 18681493
references.citation: J Pain Symptom Manage. 1997 May;13(5):254-61
references.pmid: 9185430
references.citation: J Pain Symptom Manage. 2008 Sep;36(3):268-79
references.pmid: 18538974
references.citation: Ann Pharmacother. 2005 Dec;39(12):2139-40
references.pmid: 16288064
references.citation: Ann Oncol. 2005 May;16 Suppl 4:iv132-135
references.pmid: 15923413
references.citation: Drugs. 2001;61(15):2289-307
references.pmid: 11772140
references.citation: Br J Anaesth. 1997 Dec;79(6):740-3
references.pmid: 9496205
references.citation: Drug Saf. 2003;26(13):951-73
references.pmid: 14583070
references.citation: Anesthesiology. 1989 Jun;70(6):928-34
references.pmid: 2729633
references.citation: J Clin Pharmacol. 2006 Jun;46(6):642-53
references.pmid: 16707411
references.citation: J Clin Oncol. 1998 Apr;16(4):1588-93
references.pmid: 9552070
references.citation: Lancet. 2006 Aug 12;368(9535):569-70
references.pmid: 16909503
references.citation: Br J Cancer. 2001 Mar 2;84(5):587-93
references.pmid: 11237376
references.citation: Clin Pharmacokinet. 2000 Jan;38(1):59-89
references.pmid: 10668859
references.citation: Acta Anaesthesiol Sin. 1997 Mar;35(1):25-32
references.pmid: 9212478
references.citation: Lancet. 1999 May 15;353(9165):1695-700
references.pmid: 10335806
references.citation: Br J Clin Pharmacol. 2007 Jan;63(1):121-4
references.pmid: 16939522